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ABSTRACT
Background and Aims Cannabidiol (CBD), a non-intoxicating cannabinoid found in cannabis, may be a promising
novel smoking cessation treatment due to its anxiolytic properties, minimal side effects and research showing that it
may modify drug cue salience. We used an experimental medicine approach with dependent cigarette smokers to investi-
gate if (1) overnight nicotine abstinence, compared with satiety, will produce greater attentional bias (AB), higher pleas-
antness ratings of cigarette-related stimuli and increased craving and withdrawal; and (2) CBD in comparison to placebo,
would attenuate AB, pleasantness of cigarette-related stimuli, craving and withdrawal and not produce any side effects.
Design Randomized, double-blind cross-over study with a ﬁxed satiated session followed by two overnight abstinent
sessions. Setting UK laboratory. Participants Thirty non-treatment-seeking, dependent cigarette smokers recruited
from the community. Intervention and comparator 800mgoral CBD, or matched placebo (PBO) in a counterbalanced
order Measurements AB to pictorial tobacco cues was recorded using a visual probe task and an explicit rating task.
Withdrawal, craving, side effects, heart rate and blood pressure were assessed repeatedly. Findings When participants
received PBO, tobacco abstinence increased AB (P = 0.001, d = 0.789) compared with satiety. However, CBD reversed this
effect, such that automatic AB was directed away from cigarette cues (P = 0.007, d = 0.704) and no longer differed from
satiety (P = 0.82). Compared with PBO, CBD also reduced explicit pleasantness of cigarette images (P = 0.011; d = 0.514).
Craving (Bayes factor = 7.08) and withdrawal (Bayes factor = 6.95) were unaffected by CBD, but greater in abstinence
compared with satiety. Systolic blood pressure decreased under CBD during abstinence. Conclusions A single 800-mg
oral dose of cannabidiol reduced the salience and pleasantness of cigarette cues, compared with placebo, after overnight
cigarette abstinence in dependent smokers. Cannabidiol did not inﬂuence tobacco craving or withdrawal or any subjec-
tively rated side effects.
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INTRODUCTION
More than 1.1 billion people smoke world-wide [1]. A pri-
mary addictive driver of cigarette smoking is nicotine with-
drawal. Withdrawal occurs upon cessation and includes
physiological symptoms (headaches, nausea), affective
symptoms (anxiety, depression and irritability) and im-
paired cognitive performance (delay discounting, response
inhibition) [2], which peak within the ﬁrst few days [3].
Some evidence suggests withdrawal severity predicts
relapse [3–6], prevention of which is a major challenge in
the treatment of addiction [7]. Even when using the cur-
rently most effective smoking cessation drug (varenicline),
a majority still fail to maintain long-term abstinence [8].
Nicotinic medications may also have unpleasant side ef-
fects, e.g. nausea [9].
There is mounting evidence that the endogenous
cannabinoid (eCB) system is involved in motivation for
rewards, including modulating the rewarding effects of
drugs [10–15]. In relation to nicotine dependence,
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cannabinoid receptor 1 (CB1R) antagonists, such as
rimonabant, decrease nicotine conditioned place prefer-
ence and self-administration in pre-clinical models of
addiction [16,17]. In human clinical trials, rimonabant
increased smoking abstinence rates 1.6-fold [18,19].
Although potentially effective, rimonabant was withdrawn
from the market due to serious neuropsychological side
effects.
Cannabidiol (CBD) is the second most abundant
cannabinoid in cannabis. It has been shown to have broad
therapeutic beneﬁts [20,21] and is showing initial promise
as a treatment for addiction, anxiety and schizophrenia.
The psychological properties of CBD are suggestive of a
potentially ideal drug for smoking cessation. These include
its lack of intoxicating and subjective effects [22–24],
alongside its anxiolytic [25,26] effects in humans. Its
anxiolytic properties are particularly relevant, as anxiety
is a primary symptom of tobacco withdrawal [27]. The ﬁrst
human pilot study to investigate CBD as a treatment for
nicotine dependence randomized participants to either
1 week of ad-hoc CBD or placebo inhaler to be used when
they had the urge to smoke. CBD reduced the number of
cigarettes reportedly smoked by almost 40%, in compari-
son to placebo, but did not affect craving [28]. No
neurocognitive mechanisms through which CBD may as-
sist with the treatment of smoking cessation were investi-
gated. On the basis of previous ﬁndings [29], the authors
proposed that a reduction in the salience of drug cues could
be one candidate mechanism.
Attentional bias is a potentially important in-laboratory
predictive marker of the salience of drug cues. It is height-
ened, as indexed by dot-probe tasks, during acute
abstinence [2]; predicts short-term relapse [30]; and is
thought to play a causal role in maintaining addiction
[31]. Attentional bias to tobacco stimuli at a short
(compared to longer) exposure interval is particularly
important, as tobacco abstainers show greater bias to these
cues only at short exposure [32]. CBD may reduce the
salience of smoking cues, which would be consistent with
pre-clinical, human experimental and neuroimaging
research. In human naturalistic research, cannabis with
high, in comparison to low, levels of CBD reduced cue
salience to cannabis-related stimuli in a visual probe task
[29]. This was again only observed at the short stimulus
exposure interval which taps ‘automatic’ bias, i.e. that
which is not subject to conscious cognitive control. As
such, CBD may target an important implicit process
involved in relapse. In a pre-clinical rat model of addiction,
Ren et al. [33] showed that CBD (5–20 mg/kg) attenuated
cue-induced heroin-seeking behaviour and relapse, which
was maintained for 2 weeks after CBD administration.
Furthermore, human translational pilot research showed
that a single dose of CBD can attenuate cue-induced
craving in heroin users during a 24-hour period and this
was maintained for 7 days [34]. One neuroimaging study
suggests that CBD modulates activity of areas in the brain
associated highly with salience attribution, including the
striatum, hippocampus and prefrontal cortex [35]. Taken
together, the experimental evidence provides a strong ra-
tionale to hypothesize that CBD is a potential treatment
for substance use disorders where the salience of drug cues
is key.
This is the ﬁrst study, to our knowledge, to investigate
the effects of CBD during nicotine withdrawal in humans.
We employ an experimental medicine approach to investi-
gate CBD’s potential to target processes relevant to
smoking cessation. Human laboratory studies of smoking
abstinence provide an efﬁcient, cost-effective, mechanistic
evaluation of medications for smoking behaviour [36],
which may facilitate translational research. Speciﬁcally,
we hypothesized that: (1) overnight nicotine abstinence,
compared with satiety, will produce a range of nicotine
withdrawal symptoms in dependent cigarette smokers
which include greater attentional bias (short stimulus
exposure), higher pleasantness of cigarette-related stimuli
and increased craving and withdrawal; (2) CBD in compar-
ison to placebo, would attenuate attentional bias and
pleasantness of cigarette-related stimuli, craving and
withdrawal symptomology relative to pre-drug scores;
and (3) CBD in comparison to placebo, will not produce
any signiﬁcant cardiovascular or side effects.
MATERIAL AND METHODS
Design and participants
Thirty participants attended three sessions [mean = 7.85,
standard deviation (SD) = 2.77 days between sessions].
Participants smoked as normal before their ﬁrst (baseline)
session, veriﬁed with expired carbon monoxide
(CO) ≥ 10 parts per million (p.p.m.) (Bedfont Scientiﬁc,
Harrietsham, UK). Participants then attended two sessions
after overnight (~12-hour) abstinence, veriﬁed by
CO ≤ 10 p.p.m. [37]. A double-blind, placebo-controlled,
cross-over design was used to compare the effects of
800 mg oral CBD with matched placebo (PBO) after over-
night smoking abstinence. Treatment order for abstinent
sessions was randomized and counterbalanced. Partici-
pants received the drug based on a randomization code,
balanced for gender (www.random.org), which was
concealed from experimenters until all data were collected
and entered. Drug concealment occurred through
participant-numbered, opaque, sealed envelopes. There
was a minimum washout period of 1 week between drug
sessions to preclude potential CBD carry-over effects
following previous research [23,24].
Dependent cigarette smokers were recruited from the
community through on-line message boards. Inclusion
criteria were: (i) age 18–50 years; (ii) smoking ≥ 10
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cigarettes a day for at least the last year; (iii) Fagerström
Test for Nicotine Dependence (FTND) score ≥ 4 (moderate
dependence) [38]; (iv) smoking ﬁrst cigarette within an
hour of waking; and (iv) negative drug urine screen for
all major drugs of abuse at baseline. Exclusion criteria
were: (i) use of nicotine replacement therapy/cessation
pharmacotherapy; (ii) self-reported recent use of cannabis
or other illicit drugs; (iii) recent (past 4 weeks) or ongoing
use of e-cigarettes; (iv) current mental or physical health
issues or learning impairments; (v) pregnancy or
breastfeeding; and (vi) allergies to CBD, gelatine, lactose,
microcrystalline cellulose or chocolate.
Power calculation
We calculated that n = 20 would be necessary to have
power of 95% at an alpha of 5% to detect a large effect size
of d = 0.78 (F = 0.38). This was based on the difference in
the number of cigarettes smoked pre–post 1 week of CBD
inhaler versus placebo (23.25 cigarettes) in Morgan et al.
[28]. This sample size was increased by 50%, yielding a
ﬁnal sample of 30 to adjust for ‘winner’s curse’ [39], i.e.
over-inﬂation of effect sizes from initial positive studies.
Drug administration
Participants were administered 800 mg oral CBD [pure
synthetic () CBD, STI Pharmaceuticals, Brentwood, UK]
or matched placebo (lactose powder) in identical, opaque
capsules on each testing occasion. 800 mg was chosen,
as it produces an increase in plasma concentrations
after acute administration [Cmax = 77.9, standard
error = 25 ng/ml, Tmax = 180 minutes [23]), is well
tolerated in humans, is efﬁcacious for schizophrenia [40],
increases extracellular anandamide levels [40] and should
be sufﬁcient to inﬂuence salience attribution after a single
dose [35].
Assessments
Visual probe task (Fig. 1)
This task was implemented as ameasure of attentional bias
[41]. Thirty smoking (target) and composition-matched
neutral (non-target) images were shown [42]. Each trial
beganwith a ﬁxation point (500ms). A pair of images then
appeared on the left and right of the screen for either a
short (200 ms) or long (500 ms) duration to assess auto-
matic orientating and controlled attention processing,
respectively. Image pairs were replaced by a probe (an
arrow pointing upwards or downwards) in the location of
either the neutral or smoking-related image. The probe
remained on screen until the participant responded to
identify the probe orientation (upwards or downwards)
by pressing one of two appropriate response keys as quickly
and accurately as possible (deﬁned as a ‘correct trial’ if a
correct response was made). Probes replaced the
cigarette-related and neutral images equally often. The
position of image type, probe location and stimulus
duration was counterbalanced. Trials were displayed in a
single block with each pair presented eight times, produc-
ing 80 critical trials and 32 neutral trials. The task
began with four buffer trials. Trial order was randomized
each time the task was run. The task was programmed
with Experiment Builder (SR Research, Kanata, ON,
Canada).
Pleasantness rating task (PRT)
Each trial began with a ﬁxation cross of 500 ms, followed
by either a cigarette or neutral cue, presented in a random-
ized order for 3000 ms. Stimuli were matched on bright-
ness and complexity. Cigarette stimuli involved smoking-
related scenes and were the same as the visual probe. Par-
ticipants rated the pleasantness of each image on a scale of
3 (very unpleasant) to +3 (very pleasant). Valence was
Figure 1 Trial structure for the visual probe task. Example of cigarette (right) and matched neutral stimuli (left) provided. [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]
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recorded. Three versions were available for
counterbalancing. The experiment was conducted using
Psychopy [43,44].
State questionnaires
Withdrawal was assessed with the Mood and Physical
Symptoms Scale (MPSS) [45]. Craving was assessed with
Questionnaire of Smoking Urges–Brief (QSU-B) [46].
Participants completed a six-item side-effect form with
items: ‘strong drug effect’, ‘good drug effect’, ‘willing to
take drug again’, ‘like drug effect’, ‘I have an upset
stomach’ and ‘I have a headache’. Each item was rated
on a 10-point visual analogue scale (VAS) from ‘not at
all’ to ‘extremely’.
Trait questionnaires
The FTND was used to assess nicotine dependence [38].
Anxiety was assessed with the State–Trait Anxiety Inven-
tory (STAI) [47] and depression with the Beck Depression
Inventory (BDI) [48]. A comprehensive drug history was
taken [49]. Pre-morbid verbal intelligence was indexed by
the Spot the Word task [50].
Procedure
After telephone screening eligible participants attended a
baseline ‘satiated session’, prior to which they smoked as
normal. This involved further screening assessments (CO,
urine test, pregnancy test, Spot the Word) as well as the
same assessments as on the abstinent days. On the satiated
day, participants completed state measures of craving
(QSU-B) and withdrawal (MPSS) after they were deemed
eligible (T1; +12minutes), were asked to smoke a cigarette
(Marlboro Gold) to ensure satiety (+30 minutes), then
completed a second measure of craving and withdrawal
(T2; + 35 minutes), the visual probe task (+ 60 minutes),
PRT (+68 minutes) and a ﬁnal measure of craving and
withdrawal (T3; +75 minutes). On abstinent sessions,
participants attended two ~ 3.5-hour sessions, separated
by 1 week, after overnight abstinence. They provided a
CO reading, then completed state questionnaires and car-
diovascular measures [QSU-B, MPSS, heart rate (HR),
blood pressure (BP) (T1, +5 minutes)]. CBD or matched
placebo was then administered orally (+10 minutes). After
drug administration, participants completed half the trait
questionnaires in each session. At 70 minutes (T2) and
130 (T3) minutes they again completed the MPSS, QSU-
B, HR and BP. Participants then completed the visual probe
(+180minutes) andPRT (+188minutes). At200minutes,
participants completed a ﬁnal measure of craving and
withdrawal (T4). A detailed schedule of assessments can
be found in Supporting information, Table S1. Other
assessments are reported elsewhere [51]. All participants
provided written informed consent. Ethical approval
was given by UCL Ethics Committee. Participants were
reimbursed £10 per hour.
Statistical analysis
Statistical analyses were performed in the Statistical Pack-
age for Social Scientists (SPSS version 24; IBM, Chicago, IL,
USA). Visual inspection of diagnostic plots was used to
check for normality. Where the assumption of sphericity
was violated, the Greenhouse–Geisser correction was used
and rounded to the nearest integer; η2p denotes partial eta-
squared. Outliers > 1.5 × the interquartile range (IQR)
were Winsorized to the next highest/lowest value. For the
PRT, 4.2% of the data were missing due to technical issues
and were replaced with the means of the condition. Sensi-
tivity analysis showed that Winsorization or mean imputa-
tion did not modify any result.
Only correct trials (99.97% of the data) were analysed
for the visual probe and responses > 2000 and < 200 ms
were removed. Following Mogg et al. [52], bias scores were
calculated for the visual probe and PRT, such that a positive
score indicates a bias towards cigarette cues. This was
calculated as the difference in RT between when the probe
replaced the neutral, in comparison to cigarette, stimulus
(RTneutral – RTcigarette) for the visual probe task; and as
cigarette_valence – neutral_valence for the PRT.
The visual probe and PRT were analysed using
repeated-measures analysis of variance (ANOVA) with
two a priori orthogonal Helmert contrasts to investigate
main effects. The ﬁrst describes the main effect of absti-
nence, i.e. satiated (SAT) versus abstinent (CBD). The sec-
ond describes the main effect of drug, i.e. CBD versus
PBO. For the visual probe task, an additional task-speciﬁc
factor of exposure time was included to investigate auto-
matic (short) in comparison to strategic (long) processing.
Interactions between condition and exposure were
explored via pairwise post-hoc comparisons, Bonferroni-
corrected locally within each omnibus term.
Craving (QSU) and withdrawal (MPSS) symptomology
were analysed with two repeated-measures ANOVAs
because of the difference in timing between sessions and
number of assessments of craving and withdrawal. The
ﬁrst investigated satiation (T2: immediately after a ciga-
rette) versus abstinence (T1: pre-drug administration).
The second compared CBD in comparison to PBO across
all time-points [T1 (pre-drug), T2, T3, T4]. Interactions
between condition and time were assessed with post-hoc
comparisons, Bonferroni-corrected locally within each
omnibus term.
Side effects, HR and BP were measured three times on
abstinent sessions, therefore these data were analysed with
a 2 [CBD, PBO) × 3 T1 (pre-drug), T2, T3] ANOVA.
Interactions between condition and time were assessed
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with post-hoc comparisons, Bonferroni-corrected locally
within each omnibus term.
Scaled Jeffreys–Zellner–Siow (JZS) Bayes factors (BF)
were calculated when the main effect of drug (CBD
versus PBO) was not signiﬁcant according to frequentist
statistics (P > 0.05). We used a scaled-information prior
of r = 1 [53].
Carry-over effects were assessed using an additional
between-subjects factor of ‘order’. No order effects were
found for the main analyses (as evidenced by no interac-
tions or main effects involving treatment order). Therefore,
we report results without accounting for order. As we did
not have any speciﬁc a priori hypotheses regarding covari-
ates, we did not include any, as per Kraemer [54].
RESULTS
Participant characteristics (Tables 1 & 2)
Thirty participants (14 female) took part. The sample had
amean (SD) age of 28.07 (8.66) years, with an FTND score
of 5.56 (1.13) demonstrating moderate dependence. They
smoked 13.5 (2.39) cigarettes per day, which is slightly
more than the national adult average of 11.5 [55]. Further
demographics, trait scores and cigarette smoking
information can be found in Table 1. Use of other drugs
was minimal in this population (Table 2). For conﬁrmation
of both self-reported and CO level indexed abstinence; see
Supporting information.
Attentional bias
Visual probe task (Fig. 2)
There was a main effect of abstinence (F(1,29) = 9.52,
P = 0.004, η2p = 0.27), which showed that there was a
greater attentional bias under abstinence versus satiation.
There was a main effect of drug, which was subsumed un-
der the condition × exposure interaction (F(2,58) = 4.66,
P=0.013, η2p = 0.14). The interaction showed that under
the short stimulus exposure, there was greater attentional
bias to cigarette cues in the PBO condition, in comparison
to SAT (45.15 ms, 95% CI = 71.77, 18.54, P = 0.001,
d = 0.789), as well as greater attentional bias in the PBO
condition in comparison to CBD (36.47 ms, 95%
CI = 64.18, 8.77, P = 0.007, d = 0.704), but not between
SAT and CBD (8.68 ms, 95% CI = –28.43, 11.07,
P = 0.82). Under the long stimulus exposure, none of these
comparisons were signiﬁcant. Additionally, ABwas greater
to cigarette cues under the long, in comparison to short,
exposure time for CBD (20.94 ms, 95% CI = 40.29, 5.15,
P = 0.015), but not under SAT (P = 0.263) or PBO
(P = 0.155). There was no main effect of exposure time




There was no main effect of abstinence (F(1,29) = 0.53,
P = 0.47, η2p = 0.02). There was a signiﬁcant main effect
of drug (F(1,29) = 7.41, P = 0.011, η
2p = 0.20), indicating
less bias towards cigarette stimuli on CBD compared to PBO
(0.51, 95% CI = –0.99, 0.03); d = 0.514).
Craving (Fig. 4)
Pre-drug QSU scores were greater in abstinent conditions
versus satiation (F(1,29) = 99.75, P < 0.001, η
2p = 0.78).
Table 1 Participants’ demographic and trait variables. Results are
displayed as mean (standard deviation).
n 30
Age (years) 28.07 (8.66)
FTND score 5.56 (1.13) range 4–8
Cigarettes per day 13.5 (2.39) range 10–20
Time to ﬁrst cigarette (mins) 25.5 (15.87)
Years smoked 9.55 (7.36)
Years smoking > 10+ cigarettes/day 8.17 (7.08)
Life-time quit attempts (n = 25) 3.2 (3.91)
Most successful quit attempt (days) 100.48 (163.47)
Body mass index 23.98 (7.78)
Spot the Word 48.03 (4.15)
STAI 40.53 (9.4)
BDI 10.36 (7.54)
FTND= FagerströmTest for Nicotine Dependence; STAI = Stait–Trait Inven-
tory; BDI = Beck Depression Inventory.
Table 2 Drug use history (n = the number of people who used the drug in the past year). Results are displayed as mean (standard
deviation).
Alcohol Cannabis MDMA Cocaine
n 26 17 9 9
Days since last use 6.39 (10.13) 100 (68.30) 84.66 (82.22) 100 (56.12)
Number of years used 13.08 (8.68) 8.29 (4.61) 4.55 (1.59) 3.33 (2.12)
Days per month 11.43 (8.85) 0.75 (1.30) 0.67 (1.32) 0.5 (1.15)
Typical amount per session 7.1 units (3.23) 0.87 joints (0.69) 258.33 mg (144.70) 800 mg (0.83)
MDMA = 3,4-methylenedioxymethamphetamine.
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There was no difference between CBD and PBO, pre-drug
administration (P = 0.99) conﬁrmed by a Bayesian
analysis, showing that the null was 7.08 more likely than
the alternative given the data (JZS BF = 7.08). To investi-
gate if CBD attenuated craving in comparison to PBO on
abstinent sessions, we conducted an ANOVA that showed
a main effect of time (F(2,54) = 8.34, P < 0.001
η2p = 0.22); however, there was no main effect of drug
(P=0.81) conﬁrmed bya Bayesian analysis (JZS BF=6.87)
or drug × time interaction, suggesting no difference
between CBD and PBO.
Withdrawal (Fig. 5)
Pre-drug MPSS scores was greater under abstinent condi-
tions versus satiation (F(1,29) = 29.88, P < 0.001,
η2p = 0.51), suggesting that abstinence increased with-
drawal. There was no difference between CBD and PBO,
Figure 4 Scores for the Questionnaire of Smoking Urges–Brief (QSU-B) (craving). Left panel (a) shows signiﬁcantly greater craving on abstinent
sessions before drug administration, in comparison to satiation scores after a cigarette. Right panel (b) compares cannabidiol (CBD) and matched pla-
cebo (PBO) across all time-points pre- and post-drug administration (T2 onwards). See Supporting information, Table S1 for details on timing. Esti-
mated marginal means with 95% conﬁdence interval are presented. ***P ≤ 0.001
Figure 3 Bias in pleasantness rating (calculated as cigarette valence mi-
nus neutral valence) for satiated (38 min post-cigarette) and abstinent
(188 min post-drug administration) conditions. Estimated marginal
means are presented with 95% conﬁdence interval error bars. *P ≤ 0.05
Figure 2 Attentional bias across satiated (30 min post-cigarette) and abstinent (180min post-drug administration) for both short and long exposure
times. Estimated marginal means are presented with 95% conﬁdence interval error bars. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. SAT=satiated;
CBD=cannabidiol; PBO=placebo
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pre-drug administration (P = 0.85) conﬁrmed by Bayesian
analysis showing the null was 6.95 more likely than the
alternative given the data (JZS BF = 6.95). To investigate
if CBD attenuated withdrawal in comparison to PBO on ab-
stinent sessions, we conducted an ANOVA that showed a
main effect of time (F(2,69) = 8.98, P < 0.001,
η2p = 0.24); however, there was no effect of drug
(F(1,29) = 0.22, P = 0.64, η
2p = 0.01) conﬁrmed by a
Bayesian analysis (JZS BF = 6.35) or drug × time
interaction.
Analysis of the additional MPSS questions (amount of




There was a main effect of time (F(1,39) = 33.73,
P < 0.001, η2p = 0.54) which showed that HR decreased
over time. There was no main effect of drug (P = 0.30)
conﬁrmed by a Bayesian analysis (JZS BF = 4.17) and no
interaction between drug and time.
Blood pressure (BP)
A main effect of drug (F(1,29) = 6.72, P = 0.015,
η2p = 0.19) showed higher systolic BP after PBO than after
CBD (+3.40, 95% CI = 0.72–6.08). There was a main ef-
fect of time (F(2,58) = 13.24, P< 0.001, η
2p = 0.31), which
showed that systolic BP decreased over time. There were
no main effects or interactions for diastolic BP.
Side effects
One interaction between drug and time was found for
‘headache’, but no signiﬁcant pairwise comparisons
emerged. No othermain effects of drugor interactionswere
found between drug and time. See Supporting information
for more details.
DISCUSSION
This study employed an experimental medicine approach
to investigate the effects of a single 800-mg oral dose of
CBD on nicotine withdrawal. We found evidence that,
compared to placebo, CBD reversed attentional bias to
cigarette cues in abstinent smokers, such that it was no
longer signiﬁcantly different from attentional bias when
they were satiated. Simultaneously, we observed a reduc-
tion in explicit pleasantness during abstinence, such that
cigarette stimuli were rated as less pleasant after CBD than
placebo. These neurocognitive effects occurred in the ab-
sence of any changes in subjective states of craving and
withdrawal between CBD and placebo. This suggests that
CBD may have speciﬁc effects on the evaluative and moti-
vational salience-reducing properties of drug cues, which
is consistent with clinical [29,34] and pre-clinical research
[33]. Moreover, no signiﬁcant psychoactive or side effects
were observed. These results therefore support the poten-
tial of CBD in targeting speciﬁc neurocognitive processes
in nicotine addiction.
To be speciﬁc, a reduction in the implicit salience of
drug cues of a large effect size was observed in the CBD
condition (versus placebo) after overnight abstinence in de-
pendent cigarette smokers. That is to say that participants
were over 40 ms faster to detect probes replacing smoking
(versus neutral) cues under placebo than under CBD. This
was observed in the short exposure time only, consistent
with our initial hypothesis and with previous ﬁndings
regarding attentional bias [32] and CBD [29]. The short
exposure time is related to implicit automatic processing
and initial orientation to cues, which occur outside the
individual’s explicit awareness [32,56].
These results suggest that one potential candidate
mechanism by which CBD may exert anti-addictive effects
is by normalizing the salience of drug cues. This in linewith
the incentive salience model of drug addiction [57]. Given
that attentional bias may predict smoking cessation
Figure 5 Scores for the Mood and Physical Symptoms Scale (MPSS) (withdrawal symptoms). Left panel (a) shows signiﬁcantly greater withdrawal
on abstinent sessions before drug administration, in comparison to satiation scores after a cigarette. Right panel (b) compares cannabidiol (CBD) and
matched placebo (PBO) across all time points pre- and post-drug administration (T2 onwards). See Supporting information, Table S1 for details on
timing. Estimated marginal means with 95% conﬁdence interval are presented. ***P ≤ 0.001
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outcomes [30], CBD may be useful in aiding early absti-
nence by reducing the salience of drug-related cues. How-
ever, it is unlikely that attentional bias is the only driver of
nicotine addiction, and other mechanisms require
investigation.
As well as effects of CBD on implicit attentional bias, a
reduction in explicit pleasantness for cigarettes under
CBD compared to placebowas also observed. Explicit pleas-
antness is important with regard to addiction because it
partly indexes the reinforcing value of a drug. In humans,
users of high, in comparison to low CBD : THC ratio canna-
bis showed lower self-reported pleasantness of cannabis
stimuli, which follows the same pattern as the present
study [29] andmay be related to endocannabinoid involve-
ment in hedonic experiences [58]. However, there was no
difference between abstinence and satiated sessions, which
was unexpected, as it was hypothesized and has been
shown previously [59].
The absence of CBD effects on withdrawal and craving
are surprising because, theoretically, the incentive salience
model of Robinson & Berridge [57] would suggest that a
reduction in attentional bias would be accompanied by a
reduction in craving. Moreover, Hurd et al. [34] found that
CBD reduced cue-induced craving and anxiety which was
maintained for 24 hours in heroin users (however, a differ-
ent paradigm was used). It is notable that both Morgan
et al. [28] and the present study did not ﬁnd effects on tonic
craving, therefore CBD may not be effective for all smokers
but only those suffering from heightened attentional bias
to drug cues. The incentive salience model equates craving
with wanting a drug, not liking a drug, and argues that
craving reﬂects the attribution of intense incentive salience
to reward-associated stimuli. In the present research, CBD
reduced attentional bias, arguably an index of incentive sa-
lience, but had no impact on craving. Given that craving
and attentional bias are dissociated here, with CBD speciﬁ-
cally attenuating attentional bias, this research seems to be
inconsistent with the model. It may be the observed reduc-
tion in attentional bias is a result of a general motivational
effect in that CBD may be reducing general orienting to sa-
lient cues, thus explaining the observed dissociation. Fu-
ture research should investigate whether CBD also
modiﬁes orientating to other salient stimuli such as food
cues. This has been investigated with street cannabis,
where individuals smoking cannabis high (in comparison
to low) in CBD had signiﬁcantly lower attentional bias to
both cannabis and food-related cues [29].
The neurobiological mechanism by which CBDmay ex-
ert these effects is unclear; however, a promising candidate
is through normalization of extracellular anandamide, via
inhibition of fatty acid amide hydrolase (FAAH). FAAH
inhibitors have been shown to reduce nicotine self-
administration and conditioned place preference (CPP) in
rats and monkeys as well as nicotine-induced dopamine
release in the nucleus accumbens [60–63]. Here, we were
unable to measure anandamide levels; however, this puta-
tive mechanism requires further research, as more potent
FAAH inhibitors may provide more anti-addictive effects
than CBD. This may also be the mechanism by which
CBD may alleviate psychotic symptoms in people with
schizophrenia [40].
Limitations
First, we used an experimental medicine approach to
investigate mechanistic effects of single-dose CBD during
overnight tobacco withdrawal, therefore it is unclear
whether these effects will translate to the clinic and how
long they might last. The visual probe task provides only
a cross-sectional snapshot of attentional bias in a labora-
tory setting, and may suffer from low internal reliability
[64]. In this case, ecological momentary assessment may
be more indicative of attentional bias in actual drug-taking
environments. Additionally, use of eye tracking, functional
magnetic resonance imaging (fMRI) or electroencephalo-
gram (EEG) would provide additional information on the
time–course and neural correlates of attentional bias.
Moreover, only a single dose of CBD was given; future
research needs to investigate repeated dosing and a range
of doses [65]. Finally, compliance with tobacco smoking
abstinence instructions was veriﬁed with breath CO, but
abstinence from other nicotine products was based on
self-report, therefore we could not verify objectively
that participants had not used other nicotine products.
However, craving and withdrawal scores were markedly
higher under abstinence than satiation, suggesting that
self-report was reliable.
CONCLUSIONS
This is the ﬁrst study, to our knowledge, to investigate
effects of CBD on nicotine withdrawal. After overnight
tobacco abstinence, cigarette smokers administered
800 mg CBD, in comparison to placebo, show a reduced
salience and pleasantness of cigarette cues, in the absence
of any reductions in withdrawal or craving. This study
highlights the potential utility of CBD as a treatment for
speciﬁc neurocognitive components of tobacco use disor-
der, and suggests that one potential mechanism by which
CBD may exert its effects on addiction is via a reduction
in the salience of drug cues. These results support the
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